Cuộc họp công bố kết quả kinh doanh Q2 2026 của MDxHealth (MDXH): Doanh thu phục hồi, duy trì dự báo
Doanh thu Quý 2/2026 của MDxHealth tăng 16% lên 27,2 triệu USD. Công ty duy trì dự báo doanh thu trong khoảng 110 triệu – 115 triệu USD và đặt mục tiêu đạt EBITDA điều chỉnh dương khi kết thúc năm 2026.
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.